Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1481 Views
eMediNexus 29 July 2021
SARS- CoV-2 is a novel virus with no proven therapeutic options for the management of the illness caused by it.
Several different drugs have been used for the treatment of COVID-19 since the outset of the pandemic. However, the outcomes have been mixed. Early findings from the compassionate use of remdesivir prompted FDA approval for this drug in COVID-19 management. However, later trials did notfind significant clinical benefit.
A recent study involving bromhexine in COVID-19 patients has been able to yield some positive results. The open-label, randomized trial evaluated the efficacy of early oral bromhexine therapy among COVID-19 patients with pneumonia in terms of intensive care unit (ICU) admission, rate of mechanical ventilation, and mortality. Seventy eight patients were randomized 1:1 to either bromhexine therapy or the control group (n=39 in each group). Patients in both the groups received standard therapy.
Primary outcome measure - Reduction in the rate of ICU admissions, intubation/mechanical ventilation, and 28-day mortality.
Secondary outcomes measures- Clinical improvement of symptoms (fever, dyspnea, and weakness) assessment of C-reactive protein (CRP), lactate dehydrogenase (LDH), neutrophil/lymphocyte ratio (NLR), and duration of hospital stay.
Findings –
The drug could therefore be repurposed for the treatment of patients with COVID-19.
Source: Ansarin K, Tolouian R, Ardalan M, et al. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial. Bioimpacts. 2020; 10(4): 209–215.
What message does the study give? Bromhexine has the potential to be explored further as a repurposed drug for use in patients with COVID-19. |
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}